ABSTRACT Introduction: In this study, we aimed to evaluate the most common causes of recurrent angina after coronary artery bypass grafting (CABG) and our treatment approaches applied in these patients. Methods: We included all patients who underwent CABG, with or without percutaneous coronary intervention after CABG, at our hospital from September 2013 to December 2019. Patients were divided into two groups according to the time of onset of anginal pain after CABG. Forty-five patients (58.16 ± 8.78 years) had recurrent angina in the first postoperative year after CABG and were specified as group I (early recurrence). Group II (late recurrence) comprised 82 patients (58.05 ± 8.95 years) with angina after the first year of CABG. Results: The mean preoperative left ventricular ejection fraction was 53.22 ± 8.87% in group I, and 54.7 ± 8.58% in group II (P=0.38). No significant difference was registered between groups I and II regarding preoperative angiographic findings (P>0.05). Failed grafts were found in 27.7% (n=28/101) of the grafts in group I as compared to 26.8% (n=51/190) in group II (P>0.05). Twenty-four (53.3%) patients were treated medically in group I, compared with 54 (65.8%) patients in group II (P=0.098). There was a need for intervention in 46.6% (n=21) of group I patients, and in 34.1% (n=28) of group II patients. Conclusion: Recurrent angina is a complaint that should not be neglected because most of the patients with recurrent angina are diagnosed with either native coronary or graft pathology in coronary angiography performed. Introduction study (CABG Methods 201 2019 Fortyfive Forty five 58.16 5816 58 16 (58.1 878 8 78 8.7 years early recurrence. recurrence . late 58.05 5805 05 (58.0 895 95 8.9 Results 5322 53 22 53.2 887 87 8.87 547 7 54. 858 8.58 P=0.38. P038 P P=0.38 0 38 (P=0.38) P>0.05. P005 P>0.05 (P>0.05) 277 27 27.7 n=28/101 n28101 n 28 101 (n=28/101 268 26 26.8 n=51/190 n51190 51 190 (n=51/190 Twentyfour Twenty four 53.3% 533 3 (53.3% 5 65.8% 658 65 (65.8% P=0.098. P0098 P=0.098 098 (P=0.098) 466 46 6 46.6 n=21 n21 21 (n=21 341 34 1 34.1 n=28 n28 (n=28 Conclusion performed 20 58.1 581 (58. 8. 58.0 580 89 9 532 2 53. 88 8.8 85 8.5 P03 P=0.3 (P=0.38 P00 P>0.0 (P>0.05 27. n=28/10 n2810 10 (n=28/10 26. n=51/19 n5119 19 (n=51/19 53.3 (53.3 65.8 (65.8 P009 P=0.09 09 (P=0.098 4 46. n=2 n2 (n=2 34. 58. (58 P0 P=0. (P=0.3 P>0. (P>0.0 n=28/1 n281 (n=28/1 n=51/1 n511 (n=51/1 (53. 65. (65. P=0.0 (P=0.09 n= (n= (5 P=0 (P=0. P>0 (P>0. n=28/ (n=28/ n=51/ n51 (n=51/ (53 (65 (P=0.0 (n ( P= (P=0 P> (P>0 n=51 n5 (n=51 (6 (P= (P> n=5 (n=5 (P

ABSTRACT Introduction: Coronary artery bypass grafting (CABG) in patients with left ventricular dysfunction (LVD) remains a surgical challenge and is still controversial. The aim of this study was to evaluate the effectiveness of CABG in patients with LVD. Methods: This retrospective study included a total of 160 consecutive patients (133 males, 27 females, mean age 62.1±10.12 years [range 37 to 86 years]) who had a left ventricular ejection fraction (LVEF) ≤ 45% determined by echocardiography and underwent elective isolated CABG between September 2013 and December 2018. Preoperative echocardiographic data, such as ejection fraction, left ventricular (LV) end-systolic diameter, and LV end-diastolic diameter, were collected and evaluated. Preoperatively, 85 (53.13%) patients were in New York Heart Association functional class III or IV and the mean LVEF was 38.65±5.72% (range 20 to 45). Results: The overall hospital mortality was 5% (eight patients). Late follow-up was obtained in 152 (90%) cases (median follow-up time was 56,5 [3-87] months postoperatively). During follow-up, mortality developed in 11.3% (16 patients). Mean LVEF increased significantly from 38.78±5.59% before surgery to 43.29±8.46% after surgery (P<0.01). Mean late survival, freedom from coronary reintervention, and congestive heart failure rates were 86.3±3.3%, 88.7±3.9%, and 89.4±3.1%, respectively. Conclusion: In patients with LVD, CABG can be performed with low postoperative morbidity and mortality rates. Patients with LVD could benefit from coronary bypass surgery regarding postoperative LV systolic function and higher quality of life. Introduction (CABG (LVD controversial Methods 16 133 (13 males 2 females 6211012 62 1 10 12 62.1±10.1 range 3 8 years] (LVEF 45 201 2018 data (LV endsystolic end diameter enddiastolic diastolic evaluated Preoperatively 53.13% 5313 53 13 (53.13% 3865572 38 65 5 72 38.65±5.72 45. . 45) Results eight patients. patients) followup follow up 15 90% 90 (90% median 565 56 56, 387 87 [3-87 postoperatively. postoperatively postoperatively) followup, up, 113 11 11.3 (1 3878559 78 59 38.78±5.59 4329846 43 29 46 43.29±8.46 P<0.01. P001 P P<0.01 0 01 (P<0.01) survival reintervention 86333 86.3±3.3% 88739 88 7 9 88.7±3.9% 89431 89 4 89.4±3.1% respectively Conclusion life 621101 6 62.1±10. 53.13 531 (53.13 386557 38.65±5.7 (90 [3-8 11. ( 387855 38.78±5.5 432984 43.29±8.4 P00 P<0.0 (P<0.01 8633 86.3±3.3 8873 88.7±3.9 8943 89.4±3.1 62110 62.1±10 53.1 (53.1 38655 38.65±5. (9 [3- 38785 38.78±5. 43298 43.29±8. P0 P<0. (P<0.0 863 86.3±3. 887 88.7±3. 894 89.4±3. 6211 62.1±1 53. (53. 3865 38.65±5 [3 3878 38.78±5 4329 43.29±8 P<0 (P<0. 86.3±3 88.7±3 89.4±3 621 62.1± (53 386 38.65± [ 38.78± 432 43.29± P< (P<0 86.3± 88.7± 89.4± 62.1 (5 38.65 38.78 43.29 (P< 86.3 88.7 89.4 62. 38.6 38.7 43.2 (P 86. 88. 89. 38. 43.

SUMMARY OBJECTIVE: This study aimed to investigate the effectiveness of dexamethasone in dialysis patients with COVID-19 and whether it predicts mortality. METHODS: This is a comparative cross-sectional study of 113 consecutive patients with COVID-19 with severe pneumonia signs. The patients were divided into two groups according to the use of dexamethasone treatment: group 1 (n=45) included patients who were treated with dexamethasone and group 2 (n=68) who did not receive dexamethasone. RESULTS: The mean age of both groups was 67.0±10.6 and 67.2±13.0 years, respectively (p=0.947). With respect to demographic and laboratory findings, there were no significant differences between the two groups (p>0.05). The hospitalization time of patients in group 1 was longer than that in group 2 (11 [7–17] days vs. 8 [5.3–14] days, p=0.093]. The 28-day survival rate was 54.2% in the group receiving dexamethasone treatment and 79.5% in the group not receiving dexamethasone treatment (p=0.440). CONCLUSION: Dexamethasone did not reduce mortality rates and the requirement for intensive care unit in dialysis patients with COVID-19. Larger prospective randomized clinical trials are required to associate personalized medicine with the corticosteroid treatment to select suitable patients who are more likely to show a benefit.

Abstract Introduction: The aim of this study is to investigate the change in the dimension of sinus of Valsalva in patients who underwent supracoronary ascending aorta replacement with aortic valve replacement. Methods: A total of 81 patients who underwent supracoronary ascending aorta replacement with aortic valve replacement were included. Ten of 81 patients died during the follow-up. The patients were divided into three groups according to the aortic valve diseases. Group I (n=17) included patients with bicuspid valves, group II (n=30) included patients with stenotic degenerative valves, and patients with aortic regurgitation constituted group III (n=24). In preoperative and follow-up periods, the sinus of Valsalva diameter of the patients was evaluated by echocardiographic examination. The mean age was 54.1±15.1 years. Twenty-eight (34.6%) patients were female and 12 (14.8%) patients were in New York Heart Association functional class III. Results: There was no early mortality. Late mortality was developed in 10 (12.4%) patients, 8 (9.9%) due to non-cardiac reasons. Late follow-up was obtained in 71 patients with a mean of 60±30.1 months postoperatively. During follow-up, the increase in the diameter of the sinus of Valsalva was significant in Group I (P<0.01), while in Group II and III it was insignificant (P>0.05). Conclusion: To avoid the risks associated with sinus of Valsalva dilatation, it is reasonable to replace the sinus of Valsalva in the setting of aortic valve replacement and ascending aorta replacement for bicuspid aortic valve with a dilated ascending aorta and relatively normal sinuses of Valsalva in young patients.